(ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR ...

Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.

The monotherapy trial suggested a confirmed overall-response rate of 46% and a disease-control rate of 93%. In combination with Keytruda, the confirmed overall-response rate was 71% and the ...

Pyxis Oncology needs to pave a longer cash runway. To do so, the Pfizer-partnered antibody-drug conjugate (ADC) biotech is cutting 40% of staff, slimming its programs and looking to monetize royalty ...

BOSTON and SAN CARLOS, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (“Pyxis Oncology”) (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to ...

As of Thursday, December 18, Pyxis Oncology, Inc.’s PYXS share price has dipped by 53.39%, which has investors questioning if ...

Pyxis Oncology (NASDAQ:PYXS) shares reached a new 52-week high as the clinical-stage biotech backed by pharma giant Pfizer (PFE) extended the recent winning streak into the fifth consecutive session, ...

A one-month real-world review of the Blackmagic PYXIS 12K. Image quality, RAW workflow, pros, cons, and who this full-frame camera is really for.

Well, this is a nice surprise to wake up to if you’re a Blackmagic PYXIS (6K or 12K) or URSA Broadcast G2 owner. The latest ...